Opioids

Five things for pharma marketers to know: Monday, October 2, 2017

Five things for pharma marketers to know: Monday, October 2, 2017

By

The FDA tells 75 opioid drugmakers to fund training efforts; epilepsy drug reduces seizure frequency; FDA approves Novo's fast-acting mealtime insulin

Five things for pharma marketers to know: Monday, September 25, 2017

Five things for pharma marketers to know: Monday, September 25, 2017

By

The FDA declines to approve an opioid and a treatment for rheumatoid arthritis; KKR closes WebMD buyout; 60% of teens have received the HPV vaccine

Five things for pharma marketers to know: Friday, September 22, 2017

Five things for pharma marketers to know: Friday, September 22, 2017

By

Express Scripts' Miller says new models needed to pay for CAR-T; FDA warns about Intercept drug deaths; CVS puts limits on opioid scripts

Five things for pharma marketers to know: Monday, September 18, 2017

Five things for pharma marketers to know: Monday, September 18, 2017

By

Insurers rarely require prior authorization for opioids; court of appeals voids J&J win in Advil ads suit; new California law to address drug pricing

Five things for pharma marketers to know: Thursday, August 10, 2017

Five things for pharma marketers to know: Thursday, August 10, 2017

By

One in 12 docs took payments from opioid makers; hospitals cut use of Isuprel and Nitropress after price hikes; AI helping develop ALS drugs

Five things for pharma marketers to know: Tuesday, July 25, 2017

Five things for pharma marketers to know: Tuesday, July 25, 2017

By

Biogen reports better-than-expected Spinraza sales; FDA to discuss opioid prescriptions with payers; UnitedHealth Group launches media review

Five things for pharma marketers to know: Thursday, July 6, 2017

Five things for pharma marketers to know: Thursday, July 6, 2017

By

The FDA suspends three Keytruda studies; drug and device makers gave $8 billion in payments to providers in 2016; Opdivo beat Yervoy in skin-cancer trial

Five things for pharma marketers to know: Thursday, June 22, 2017

Five things for pharma marketers to know: Thursday, June 22, 2017

By

The FDA plans public meeting to encourage generic competition; Mylan reportedly offered rebates to six Medicaid programs; Republicans to present draft bill for Obamacare replacement

Drugmakers must take the lead on opioid epidemic comms, say experts

Drugmakers must take the lead on opioid epidemic comms, say experts

By

Drugmakers are increasingly facing blame from regulators, lawmakers, and the public as the list of lawsuits and investigations at the state and local levels grows.

Five things for pharma marketers to know: Tuesday, May 16, 2017

Five things for pharma marketers to know: Tuesday, May 16, 2017

By

A New York county sues drugmakers over opioid marketing; AstraZeneca files suit against GSK exec; Thermo Fisher acquires biologics firms

Purdue Pharma hires new VP of public affairs, communications

Purdue Pharma hires new VP of public affairs, communications

By

Josephine Martin was previously EVP of public affairs at PhRMA.

Five things for pharma marketers to know: Thursday, April 20, 2017

Five things for pharma marketers to know: Thursday, April 20, 2017

By

Tesaro discloses price for new drug that differs from FDA-approved dosage; uniQure discontinues Glybera; O'Reilly leaves Fox

Pacira, Trinity Health aim to address opioid use in surgeries

Pacira, Trinity Health aim to address opioid use in surgeries

By

Pacira also recently announced a partnership with Johnson & Johnson to co-promote its pain injection for certain surgeries.

Five things for pharma marketers to know: Thursday, March 30, 2016

Five things for pharma marketers to know: Thursday, March 30, 2016

By

Novartis CAR-T drug receives priority review; addiction center's ad compares addiction to cancer; Arizona passes off-label law

Senate committee launches investigation into opioid marketing

Senate committee launches investigation into opioid marketing

By

The committee is seeking information about the companies' sales and marketing strategies.

Five things for pharma marketers to know: Monday, February 13, 2016

Five things for pharma marketers to know: Monday, February 13, 2016

By

Sanofi to sell five OTC drugs to Ipsen; Teva reports 33% revenue growth in Q4; Regeneron issued subpoena about support of nonprofits

Five things for pharma marketers to know: Thursday, December 15, 2016

Five things for pharma marketers to know: Thursday, December 15, 2016

By

Drugmakers promote new type of opioid with unproven results; Heritage execs charged for price-fixing generics; Pershing sells more Valeant shares

Five things for pharma marketers to know: Thursday, October 20, 2016

Five things for pharma marketers to know: Thursday, October 20, 2016

By

Chicago to require pharma reps to track their calls; GlaxoSmithKline joins Instagram; Lilly receives accelerated approval for cancer drug

Five things for pharma marketers to know: Monday, May 16, 2016

Five things for pharma marketers to know: Monday, May 16, 2016

By

Pfizer buys Anacor; Harvard Medical School loosens rules for faculty ties to pharma; Vermont poised to pass price transparency bill

Five things for pharma marketers to know: Friday, May 6, 2016

Five things for pharma marketers to know: Friday, May 6, 2016

By

Investigation says Oxycontin wears off sooner than it claims; PBMs and insurers anticipate high biosimilar prices; Valeant forms pricing committee

Five things for pharma marketers to know: Thursday, May 5, 2016

Five things for pharma marketers to know: Thursday, May 5, 2016

By

U.S. Keytruda sales miss mark; the CDC warns parents to try therapy before drugs for children with ADHD; FDA panel recommends training for opioid prescribers

Five things for pharma marketers to know: Thursday, September 10, 2015

Five things for pharma marketers to know: Thursday, September 10, 2015

By

Cardiologists say that up to 15% of their patients could be on PCSK9 inhibitors next year; FDA committee to evaluate new Oxycodone version

Five things for pharma marketers to know: Thursday, March 26

Five things for pharma marketers to know: Thursday, March 26

By

Regeneron's Eylea won its fourth indication; Sun Pharma wants to revive trust in its products; confidentiality agreements keep Amgen from telling patients their cancer risk

Five things for pharma marketers to know: Monday, February 2

Five things for pharma marketers to know: Monday, February 2

By By

Pfizer ends spinal muscular atrophy collaboration; abuse-deterrent Zohydro scores approval; measles outbreak at Disneyland linked to 36 cases.